John F. Langenheim - Concepedia

Author

John F. Langenheim

Also Known As

Ferguson, Susan D., J.F. Langenheim, John F. Langenheim, John F Langenheim, John F. Langenheim, John Fairbanks Langenheim, John Langenheim, Langenheim, John

Publications

593

Citations

H-Index

Concepts

All Affiliations

Clemson University Prisma Health Medical College of Wisconsin Birmingham VA Medical Center University of Alabama at Birmingham

About

John F. Langenheim is an author at Clemson University specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	302
2	Cell Biology	9	9	260
3	Natural Sciences	3	3	70
4	Biochemistry	3	3	57
5	Biomolecular Engineering	1	1	25

John F. Langenheim

Publications

582

Citations

H-Index

Page 1

	Year	Citations
Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis Byung Gak Kim, Jung‐Yoon Yoo, Tae Hoon Kim, Human Reproduction	2015	113
Growth Hormone Signaling in Human T47D Breast Cancer Cells: Potential Role for a Growth Hormone Receptor-Prolactin Receptor Complex Jie Xu, Yue Zhang, Philip Berry, Molecular Endocrinology	2011	65
The Role of Prolactin Receptor in GH Signaling in Breast Cancer Cells Jie Xu, Dongmei Sun, Jing Jiang, Molecular Endocrinology Breast OncologyImmunologyTumor BiologyGh SensitivitySignaling Pathway	2012	54
Activation of Growth Hormone Receptors by Growth Hormone and Growth Hormone Antagonist Dimers: Insights into Receptor Triggering Ning Yang, John F. Langenheim, Xiangdong Wang, Molecular Endocrinology Dimer PartnerDisulfide LinkageHuman GrowthMolecular BiologySignaling Pathway	2007	52
Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells Michele L. Scotti, John F. Langenheim, Seth Tomblyn, Breast Cancer Research and Treatment Prolactin Receptor AntagonistBreast OncologyMedicineHormonal ReceptorAdditive Effects	2007	46
Two Wrongs Can Make a Right: Dimers of Prolactin and Growth Hormone Receptor Antagonists Behave as Agonists John F. Langenheim, Dunyong Tan, Ameae M. Walker, Molecular Endocrinology Molecular BiologyPharmacotherapyDimeric FormsMolecular PharmacologySignaling Pathway	2005	30
Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling Thai H. Tran, Fransiscus E. Utama, Takahiro Sato, Clinical Cancer Research	2018	27
Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide John F. Langenheim, Wen Y. Chen Journal of Endocrinology Human GrowthPeptide EngineeringGlycobiologyImmunologyGastrointestinal Peptide Hormone	2009	25
GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers Ying Liu, Yue Zhang, Jing Jiang, Molecular Endocrinology Receptor HomodimersSignal TransductionRepresentation TheoryBiochemistrySignaling Pathway	2016	24
High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer Inna Chervoneva, Amy R. Peck, Yunguang Sun, JCO Precision Oncology	2023	18

Page 1